
![]() |
In July 2002, The FDA and Eli
Lilly Company announced that Alimta (pemetrexed) would be available
to patients with malignant mesothelioma. The drug, is not yet
fully FDA approved, but is available to "qualified patients
who have been diagnosed with malignant pleural mesothelioma
and have not yet received treatment." The FDA allows Alimta
to be used under "Expanded Access Program," that allows
new treatments available to patients with diseases like mesothelioma
where treatment options are limited. Under the program, patients
with mesothelioma can get Alimta during the FDA review process.
|